Latest Conference Articles

Incyte announced that ruxolitinib cream has received validation for its European marketing authorization application from the European Medicines Agency.

In this video interview, Jeff Yu, MD, talks about what he's looking forward to at the 2021 American College of Allergy, Asthma & Immunology (ACAAI) annual scientific meeting.

Sessions with a laser focus on dermatologic issues ranging from new JAK inhibitors to disparities in atopic dermatitis anchor the opening day of the 2021 American College of Allergy, Asthma & Immunology (ACAAI) annual scientific meeting.

In this video, Ama Alexis, MD, tells us what we have to look forward to at the ACAAI conference this week.

Jonathan M. Spergel, MD, PhD, FACAAI discusses what there is to look forward to at the ACAAI conference and what he's highlighting at the event.

In this video, we talk to Michael Gold, MD, about the 11th annual New Frontiers in Cosmetic Medicine and Medical Dermatology symposium. He tells us the highlights of the conference and what makes it stands out from the rest.

Mark G. Lebwohl, MD, presents on what dermatologists need to know about the newest psoriasis studies during the Fall Clinical Dermatology Conference.

FDA approval of ruxolitinib (Opzelura, Incyte) adds the first new topical anti-inflammatory to the atopic dermatitis (AD) armamentarium in 50 years, but boxed warnings raise questions.

Botulinum type A injections are widely used across the dermatology and aesthetic medicine specialties. At the Fall Clinical Dermatology Conference 2021, Mark S Nestor, MD, PhD, highlights how to optimize the neurotoxin to improve patient care.

People are born with sterile skin and then gain microbiota throughout their life. Lawrence J. Green, MD, FAAD, explains how this affects the skin barrier and ultimately plays a role in atopic dermatitis at the 2021 Fall Clinical Dermatology Conference.

ICYMI, some of this week’s featured content includes an exclusive interview about eczema, and articles on a new tralokinumab data, apremilast as a combination treatment, and more.

In a video onsite at Fall Clinical Dermatology Conference, Darrell S. Rigel, MD, MS, highlights, in his own words, the potential of GEP as an adjunct to biopsy in melanoma detection.

Lawrence Eichenfield, MD, provides the newest updates in pediatric patient care, with a special update on COVID-19 skin symptoms in children.

LEO Pharma releases the 16-week data regarding tralokinumab (Adtralza; LEO Pharma) as a treatment for adolescent patients aged 12 to 17 years.

Cantharidin 0.7% could be an emerging standard for molluscum treatment.

How can GEP be applied to melanoma diagnosis and treatment? Darrel Rigel, MD, MS, answers these questions and dives into the data at Fall Clinical Dermatology Conference 2021.

Neal Bhatia, MD, explores steroid alternatives in his presentation at the Fall Clinical Dermatology Conference.

Click here to answer this week's poll.

Which is more worrisome, neonatal or infantile acne? An expert answered this question and more during Maui Derm NP+PA Fall 2021’s update on acne and rosacea.

Factors include extent of disease, the latest findings on agents’ efficacy, and even patient weight.

Hilary Baldwin, MD, presents on keloids in light skin patients, hypopigmentation after treatment, to stitch or not to stitch, and more.

In part 2 of this skin cancer report from the American Academy of Dermatology Virtual Meeting Experience 2021 (AAD VMX), an expert shares pearls on regular medication reviews.

Voltaire-X study data shows that switching several times between Cyltezo and Humira results in similar pharmacokinetics, efficacy, immunogenicity, and safety in people with moderate to severe chronic plaque psoriasis.

Phase 3 trial of Otezla shows improved measures of disease severity in adults with mild to moderate plaque psoriasis regardless of their Body Surface Area affected by the disease.

Incyte's Phase 2 study evaluating ruxolitinib cream for vitiligo meets primary endpoint, shows improvement in body and facial repigmentation compared to placebo.

Tremfya phase 3 data shows skin clearance rates were maintained at 5 years with 55.5% of patients achieving an IGA score of 0% and 53% achieving PASI 100 response in VOYAGE 2 trial.

There is a dire need to improve the clinical tools dermatologists use to assess the severity of acne scars. This 3D imaging technique may help, according to a recent study presented at the 2020 virtual American Society for Dermatologic Surgery (ASDS) meeting.

A recent study underscores the need for a consistent scale to grade risk levels of cutaneous squamous cell carcinoma (SCC), particularly poorly differentiated tumors, according to study authors who presented at the 2020 virtual American Society for Dermatologic Surgery (ASDS) meeting.